Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verastem, Inc. (VSTM) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including Forms 8-K, 10-K, 10-Q, and registration statements filed with the U.S. Securities and Exchange Commission. Verastem’s filings document its status as a Nasdaq-listed biopharmaceutical issuer focused on RAS/MAPK pathway-driven cancers, with common stock registered on The Nasdaq Capital Market under the symbol VSTM.
Recent Form 8-K reports highlight several important areas for investors: underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3, preliminary and updated clinical data for the KRAS G12D inhibitor VS-7375, and company communications regarding AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. These current reports also reference updated corporate presentations and conference materials that outline Verastem’s pipeline and strategy.
For a biopharmaceutical company like Verastem, periodic reports such as Forms 10-K and 10-Q (when available) typically contain detailed information on research and development spending, commercialization activities for AVMAPKI FAKZYNJA CO-PACK, risk factors related to oncology drug development, and the status of key clinical programs such as RAMP 301, RAMP 205, and VS-7375-101. Capital structure changes, including equity offerings and warrant terms, are also described in registration statements and accompanying exhibits.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain complex sections in plain language, highlight material events, and surface items of interest such as financing transactions, clinical trial disclosures, and changes in capital markets activity. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks for Verastem, review details of public offerings and warrant structures, and explore how regulatory filings align with the company’s oncology pipeline and commercial strategy.
Verastem, Inc. (VSTM) director reports option exercise and share sale. On 11/21/2025, the reporting person exercised stock options for 6,250 shares of common stock at an exercise price of
Verastem, Inc. (VSTM) director reported an open-market sale of common stock. On 11/21/2025, the reporting person sold 8,550 shares of Verastem common stock at a weighted average price of $10.00 per share, with individual trades executed between $10.00 and $10.01. The sales were made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a set schedule. After these transactions, the reporting person beneficially owns 8,666 shares of Verastem common stock directly.
Verastem, Inc. (VSTM) reported insider stock sales by its President and CEO, who is also a director. The reporting person sold 2,000 shares of common stock on each of 11/21/2025, 11/24/2025, and 11/25/2025, all at a price of $10 per share. These transactions are marked with transaction code "S," indicating open market or private sales.
After these sales, the reporting person beneficially owned 432,818 shares of Verastem common stock directly. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, which is intended to provide an affirmative defense for trading while limiting discretion over the timing and amount of trades.
Verastem, Inc. entered into an underwriting agreement for an underwritten public offering of 8,543,794 shares of common stock and pre-funded warrants to purchase up to 3,870,000 shares, with underwriters exercising in full an option for an additional 1,862,069 shares. The shares are priced at $7.25 each and the pre-funded warrants at $7.2499, reflecting a $0.0001 exercise price per warrant share. Verastem expects to receive approximately $96.9 million in net proceeds from this offering, which is being conducted under an effective Form S-3 shelf registration statement, with closing expected on or about November 17, 2025, subject to customary conditions.
Verastem, Inc. is conducting a public offering of 8,543,794 shares of common stock and pre-funded warrants to purchase up to 3,870,000 additional shares, at $7.25 per share and $7.2499 per pre-funded warrant. The deal is expected to raise approximately $84.1 million in net proceeds, or about $96.9 million if underwriters fully exercise their 1,862,069-share option. Verastem plans to use the cash to commercialize its FDA-accelerated approved AVMAPKI FAKZYNJA CO-PACK for KRAS mutant recurrent low grade serous ovarian cancer, advance clinical development of avutometinib, defactinib and VS-7375, and for working capital and general corporate purposes. The company estimates 75,292,640 shares outstanding after the offering (assuming no warrant exercises), and notes investors will face immediate dilution of $6.56 per share based on the $7.25 offering price.
Verastem, Inc. (VSTM) launched a preliminary prospectus supplement under Rule 424(b)(5) for a primary offering of common stock. The company also granted underwriters a 30‑day option to purchase additional shares, subject to customary underwriting discounts and commissions.
The company states its common stock last closed at $8.51 on The Nasdaq Capital Market on November 12, 2025. Net proceeds are intended to fund commercial activities for the AVMAPKI FAKZYNJA CO‑PACK in low‑grade serous ovarian cancer, continue clinical R&D for avutometinib, defactinib and VS‑7375, and for working capital and general corporate purposes.
As context, shares outstanding were 66,748,846 as of September 30, 2025. The prospectus notes a 60‑day lock‑up for the company and its directors and officers, with Jefferies, Guggenheim and Cantor as bookrunners. AVMAPKI FAKZYNJA CO‑PACK received FDA accelerated approval on May 8, 2025 for KRAS‑mutant recurrent LGSOC, with continued approval contingent on confirmatory data.
Verastem (VSTM) disclosed insider transactions by its President and CEO, reported as a director and officer. On 11/03/2025, the reporting person sold 1,299 shares at $9.35 to satisfy statutory tax withholding tied to RSU vesting, and separately sold 2,000 shares at $10.00 pursuant to a Rule 10b5-1 trading plan. Following these transactions, the reporting person beneficially owned 438,818 shares, held directly.
Verastem, Inc. filed a Form S-8 to register 400,000 shares under its 2014 Inducement Award Program. The filing uses General Instruction E to incorporate prior S‑8 registrations by reference.
The registration supports equity grants designed to attract and retain personnel through inducement awards. Standard exhibits include the legal opinion, auditor consent, and filing fee table. The statement was signed by President and CEO Daniel Paterson and other officers and directors.
Verastem (VSTM) filed its Q3 2025 10‑Q, marking its first full quarter of U.S. sales for AVMAPKI FAKZYNJA CO‑PACK. Product revenue reached $11.2 million for the quarter, reflecting initial commercialization following FDA approval on May 8, 2025. Cost of sales totaled $2.0 million, including $0.3 million of intangible amortization.
The company reported a net loss of $98.5 million$55.9 million non‑cash loss from the change in fair value of warrant liability. Cash and cash equivalents were $137.7 million at September 30, 2025. Operating cash use was $107.6 million year‑to‑date, offset by financing inflows from a $75.0 million note issuance, equity transactions, and warrant exercises.
The filing states substantial doubt about the company’s ability to continue as a going concern over the next 12 months as it scales commercialization and R&D. A Note Purchase Agreement provides revenue participation of 1.00% on the first $100 million of annual net sales of included products, potentially increasing to 2.00% if all $150 million notes are purchased. Shares outstanding were 66,776,006 as of November 3, 2025.
Verastem, Inc. (VSTM) filed an 8-K stating it reported financial results for the quarter ended September 30, 2025. The company furnished its earnings release as Exhibit 99.1 and posted an updated corporate presentation as Exhibit 99.2, both dated November 4, 2025.
This 8-K is an administrative disclosure that directs readers to the attached exhibits for details on operating performance and business updates. Verastem’s common stock trades on The Nasdaq Capital Market under the symbol VSTM.
FAQ
What is the current stock price of Verastem (VSTM)?
What is the market cap of Verastem (VSTM)?
